BridgeBio Pharma Stock (NASDAQ:BBIO)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$26.49

52W Range

$21.62 - $44.32

50D Avg

$25.76

200D Avg

$26.62

Market Cap

$5.25B

Avg Vol (3M)

$2.07M

Beta

1.09

Div Yield

-

BBIO Company Profile


BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

550

IPO Date

Jun 27, 2019

Website

BBIO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 20Dec 19
License$8.00M$13.80M

Fiscal year ends in Dec 23 | Currency in USD

BBIO Financial Summary


Dec 23Dec 22Dec 21
Revenue$9.30M$77.65M$69.72M
Operating Income$-607.37M$-471.87M$-579.75M
Net Income$-643.20M$-493.96M$-639.30M
EBITDA$-574.64M$-353.68M$-539.68M
Basic EPS-$-3.35$-4.43
Diluted EPS-$-3.35$-4.43

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
PTCTPTC Therapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
DAWNDay One Biopharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
KRYSKrystal Biotech, Inc.
ABOSAcumen Pharmaceuticals, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
TERNTerns Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals, Inc.